Other Information.
−Removed: (c) During the quarter ended March 31, 2025, no
+Added: (c) During the quarter ended June 30, 2025, no
director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
8 unchanged sentences
(incorporated by reference to Exhibit 3.3 to our Annual Report on Form 10-K filed on April 15, 2025)
−Removed: March 2025 Promissory Note by and between Apimeds Pharmaceuticals US, Inc.
−Removed: and Apimeds, Inc., dated March 21, 2025 (incorporated by reference to Exhibit 10.26 to our Annual Report on Form 10-K filed on April 15, 2025 )
+Added: Amendment to May 2024 Promissory Note by and between Apimeds Pharmaceuticals US, Inc.
+Added: and Apimeds, Inc., dated May 16, 2025
+Added: Amendment to August 2024 Promissory Note by and between Apimeds Pharmaceuticals US, Inc.
+Added: and Apimeds, Inc., dated May 16, 2025
+Added: Amendment to March 2025 Promissory Note by and between Apimeds Pharmaceuticals US, Inc.
+Added: and Apimeds, Inc., dated May 16, 2025
Rule 13a-14(a) Certification by Principal Executive Officer
9 unchanged sentences
Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)
−Removed: Filed or furnished with this Report.
+Added: Filed or furnished with
+Added: this Quarterly Report.
Pursuant to the requirements of the Securities
1 unchanged sentence
APIMEDS PHARMACEUTICALS US, INC.
−Removed: /s/ Erik Emerson
−Removed: Chief Executive Officer
−Removed: (Principal Executive Officer)
+Added: August 19 , 2025
+Added: Chief Financial Officer
+Added: (Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.